news & views demon strated that mtor negatively regulates proinflammatory cytokine production in monocytes, macrophages and peripheral dendritic cells following contact with Gram-negative and Gram-positive stimuli. Hence, inhibition of mtor in these cells super activates the pro inflammatory protein complex transcription factor nFκB but blocks the anti-inflammatory trans cription factor encoded by STAT3, thereby increasing the production of pro inflammatory cyto kines such as interleukin 12, interleukin 23 and tumor necrosis factor but suppressing antiinflammatory cytokines like interleukin 10 ( Figure 1) . the immunostimulatory properties of rapamycin have to be balanced against the role of mtor in the induction of regulatory t cells (t reG ), which cause the downregulation of antigen-specific immune responses, a primary clinical target in allogeneic transplantation. Pharmacological inhibition or genetic ablation of mtor might induce the pivotal t reG -specific trans cription factor FoXP3 protein in effector CD4 + t cells, thereby fostering the differentiation of helper t cells into t reG . 9 although fostering t reG production by mtor inhibitors in murine transplant models extended allograft survival, a study in human renal transplant recipients was not able to show that rapamycin ameliorates chronic allograft injury despite the induction of significant numbers of CD4 + and CD25 + t reG . 10 these findings make reference to mtor inhibitors as simple cell-cycle blocking immunosuppressants no longer possible. the adverse effects and seemingly weak efficiency of rapamycin in transplant recipients might reflect the highly divergent functions of mtor in different immunocompetent cells (Figure 1 ). maybe we can be more explicit and state that the recog nition that targeting mtor also boosts innate and adaptive effector arms of the immune system should lead the nephrology community to reconsider whether rapamycin should have an important role in clinical transplantation, or whether its use should instead be confined to exceptional cases. glomerulAr dISeASe
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Sugars and immune complex formation in IgA nephropathy
Jonathan Barratt and Frank Eitner
In vitro evidence suggests that immune complex formation in IgA nephropathy is determined by the sugar content of the IgA1 hinge region. Absence of galactose residues in this region renders the IgA1 molecule immunogenic.
mesangial deposition of iga is the principal trigger for the development of glomerulonephritis in iga nephropathy (igan).
recurrence of iga deposition in the majority of recipients of renal allografts suggests that this iga is derived from a circulating nature reviews | nephrology
news & views pool of pathogenic iga molecules. serum levels of iga do not correlate, however, with disease activity or severity, which gave rise to the belief that only a small percentage of serum iga carries igan pathogenic potential. 1 two of the principal factors thought to contribute to iga pathogenic potential are the composition of O-linked sugars in the iga1 hinge region and the variable propensity of iga1 to form large immune complexes. 2 Hitoshi suzuki and colleagues 3 present evidence that the composi tion of iga1 hinge region sugars directly influences immune complex formation by deter mining the immuno genicity of the iga1 molecule and the generation of anti-iga1 igG autoantibodies.
iga1 is one of the very few serum proteins to possess O-linked sugars. the fact that these O-linked sugars are clustered within a relatively short segment of the iga1 protein backbone (the so-called hinge region) means they might have a considerable effect on iga1 function. 4 Furthermore, the composition of O-glycans can vary widely among iga1 molecules, which results in a variety of iga1 O-glycoforms with potentially differ ent biological characteristics. suzuki et al. 3 have obtained in vitro data showing that igG produced by B cells isolated from patients with igan binds to poorly galactosy lated iga1 and is capable of triggering the formation of iga1-igG immune complexes. the researchers suggest that the anti-iga1 igG autoantibodies they identified in the serum of patients with igan are the principal driver for iga immune complex formation in patients with igan.
an increase in the proportion of serum iga molecules that are poorly O-galactosylated has been one of the most consistent findings in studies of igan over the past decade.
1,2 Perhaps more importantly, mesangial iga eluted directly from g lomer u li pre dominantly comprises these poorly galactosylated iga1 O -g lycofor ms, which strongly implicates the composition of glycans in the iga1 hinge region in the mechanism of mesangial iga1 deposition. 5 Consistent with these observations, poorly galactosylated iga1 O-glycoforms are more likely to bind to mesangial matrix proteins and activate mesangial cells and complement than their heavily galactosylated counterparts. 2 evidence from suzuki et al. also suggests that hinge region O-glycans protect iga1 from recognition by the immune system and that iga1 O-glycoforms with low levels of galactose have increased immunogenic potential.
why patients with igan have excess amounts of poorly galactosylated iga1 O-glycoforms in their serum remains unknown. a number of explanations have been put forward, including an enzymatic defect in iga1 O-glycosylation that is, at least in part, inherited.
6 one alternative explanation is that poorly O-galactosylated iga1 is in fact 'normal' iga that should have been secreted at mucosal surfaces but has mistakenly found its way into the circulation. in fact, the pattern of O-glycosylation is different between mucosal and serum iga1 in the same indivi dual and iga1 directed against mucosal pathogens is poorly O-galactosylated compared with iga1 against systemic antigens.
7 these findings combined with the reduced iga1-secreting plasma cell numbers at mucosal sites and increased numbers in the bone marrow in patients with igan suggests that, in these patients, iga production is shifted from mucosal to systemic sites. 8 the result of this shift is secretion into the circulation of high levels of mucosal-type (poorly galactosylated) iga1 molecules with biological proper ties ill-suited to the systemic circulation.
irrespective of the reasons for the high circulating levels of poorly galactosylated iga1 O-glycoforms, little data exist to explain why igG autoantibodies should develop in igan. one intriguing possibility put forward by suzuki and colleagues is that anti-iga1 igG autoantibodies could in fact be antibodies specific for bacterial and viral surface glyco proteins and that recognition of poorly g a l a c to s y l ate d ig a 1 O-glycoforms by igG is an unfortunate incident of 'molecular mimicry' . such a link between microbial infection and iga immune complex formation might help explain the association of mucosal infection with macroscopic hematuria in igan. During a normal response to infection, serum levels of microbial-specific igG rise, a proportion of this igG will be specific for microbial cell surface sugars. in indivi duals with persistently high serum levels of poorly galactosy lated iga1 O-glycoforms, a sudden rise in glycan-specific igG might therefore precipitate iga immune complex formation. a sudden increase in immune complex levels might then lead to rapid glomerular iga deposition, mesangial cell and complement activation and glomerular hematuria. an increase in circulating iga immune complex levels has been reported during episodes of macroscopic hematuria. 9 with the identification and characterization of anti-iga1 igG autoantibodies we have a better appreciation of the interrelationship between iga1 O-glycosylation and immune complex formation in igan. However, to fully understand the implications of these data, the pathogenic importance of iga1-igG immune complexes in igan must be clarified. the relative paucity of mesangial igG staining in most biopsy series of igan raises questions as to the in vivo pathological role of such complexes. suzuki et al. have already suggested that measurement of anti-iga igG autoantibodies might in the future be the basis of a noninvasive diagnostic test for igan. these researchers have also published work supporting an elisa-based method for measuring the proportion of serum iga that is poorly galactosylated; an assay that combines both of these measurements could be a powerful diagnostic tool for igan. 10 However, studies need to confirm these findings in different patient cohorts and need to validate the diagnostic specificities, sensitivities and predictive values of these assays. Finally, convincing evidence that igG-driven iga immune complex formation has a pathological role in patients with igan needs to be presented. 
John Cunningham
Vitamin d insufficiency is endemic amongst renal transplant recipients, as it is in other individuals with chronic diseases, both within and beyond nephrology. Few data exist to guide vitamin d replacement strategies, but indirect evidence points to likely skeletal, and possibly extraskeletal, benefits from supplementation.
the scourge of vitamin D deficiency and rickets was of such concern in the previtamin D era that it resulted in the publication of at least one journal, aptly named The Cripples' Journal, which focused largely on diseases related to vitamin D deficiency. the stated aim of that journal was "to deal as comprehensively as possible with all subjects affecting orthopaedics," to "appeal to all institutions, medical men, nursing staffs and helpers" and finally to "use its influence in the task of moulding public opinion". 1 appreciation of the beneficial effects of adequate sun exposure and the availability of the therapeutic vitamin D supplements, cholecalciferol and ergocalciferol, have greatly reduced-although not eliminatedthese diseases, whose prevalence remains high in vulnerable pockets of individuals in general 'healthy' populations and higher still in patients with chronic diseases of almost any kind. 2 analysis of the renal transplant population provides an instructive case in point. Patients entering the world of transplantation, particularly those who have had an extended period on maintenance dialysis, exhibit a wide range of disturbances of bone and mineral metabolism, the main clinical expression of which is a very high fracture rate. the role of deficiency of native vitamin D in the genesis of this skeletal morbidity and the associated mineral metab olism disturbances has received surprisingly little attention, with the main focus being instead on the adequacy, or other wise, of calcitriol generation by the renal allograft and on the utility of antiresorptive agents in preventing accelerated bone loss.
3,4 the vitamin D status of renal transplant recipients is further compromised by sun avoidance, immunosuppressive agents and also possibly by phosphatonin-driven catabolism of 25-hydroxyvitamin D. 5 Courbebaisse et al. 6 have published a study of 49 renal transplant recipients treated with a regimen of chole calciferol 100,000 iu once every 2 weeks from month 4 to month 6 (the equivalent of about 7,000 iu per day) after transplantation and 100,000 iu once every 8 weeks from month 6 to month 12 (the equivalent of about 1,800 iu per day). serum concentra tions of calcium, phosphate, 25-hydroxy vitamin D and para thyroid hormone (PtH) in these patients were compared with those in 47 untreated patients who had similar baseline character istics. the national Kidney Foundation/Kidney Disease outcomes Quality initiative (nKF-KDoQi) guidelines for the initiation of vitamin D therapy in chronic kidney disease and following renal transplantation were used to identify suitable patients and to gauge the adequacy of their response, but the cutoff value recom mended (30 ng/ml) has limited validity and would be seen by many as inappropriately low. median 25-hydroxyvitamin D concentration increased from 14 ng/ml to 43 ng/ml between months 4 and 6 in treated patients and remained at or below 30 ng/ml in only 6% of treated patients at 6 months, although this figure had increased to 51% by 12 months. in the control group, only three of 47 patients (6%) had a serum 25-hydroxyvitamin D level above 30 ng/ml at 12 months. treated patients exhibited minor transient increases in serum calcium and phosphate levels with small, sustained reductions in serum PtH.
the results and the design of this study need to be considered in the context of several other issues that are at best only partially resolved. For example, more detailed analysis of the effect of cholecalciferol administration on vitamin D metabolism would be very interesting. were the reductions in PtH attributable to increased circulating calcitriol concentration or were they a result of the increased 25-hydroxy vitamin concentration either acting directly as the vitamin D receptor ligand or indirectly via local generation of calcitriol in the parathyroid gland? what constitutes unequivocal vitamin D sufficiency in the renal transplant recipient, or indeed in anybody else? various definitions have been applied including the threshold for elevation of PtH, the threshold for abolition of the seasonal variation of 25-hydroxyvitamin D concentration and the top of the dose-response curve relating 25-hydroxyvitamin D concentration
